Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r) agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the effect of dulaglutide, a once-weekly GLP-1r agonist, on human LFC are scarce. This study examined the effect of dulaglutide on LFC in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).Methods Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India. Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care, based on a predefined computer-generated number with a 1:1 allocation that was concealed using serially numbered, opaque, sealed envelopes. The primary endpoint was the difference of the change in LFC from 0 (baseline) to 24 weeks between groups. The secondary outcome measures included the difference of the change in pancreatic fat content (PFC), change in liver stiffness measurement (LSM in kPa) measured by vibration-controlled transient elastography, and change in liver enzymes.Results Eighty-eight patients were screened; 32 were randomly assigned to the dulaglutide group and 32 to the control group. Overall, 52 participants were included for per-protocol analysis: those who had MRI-PDFF data at baseline and week 24. Dulaglutide treatment resulted in a control-corrected absolute change in LFC of -3.5% (95% CI -6.6, -0.4; p = 0.025) and relative change of -26.4% (-44.2, -8.6; p = 0.004), corresponding to a 2.6-fold greater reduction. Dulaglutide-treated participants also showed a significant reduction in γ-glutamyl transpeptidase (GGT) levels (mean between-group difference -13.1 U/l [95% CI -24.4, -1.8]; p = 0.025) and non-significant reductions in aspartate aminotransferase (AST) (-9.3 U/l [-19.5, 1.0]; p = 0.075) and alanine aminotransferase (ALT) levels (-13.1 U/l [-24.4, 2.5]; p = 0.10). Absolute changes in PFC (-1.4% [-3.2, 0.3]; p = 0.106) and LSM (-1.31 kPa [-2.99, 0.37]; p = 0.123) were not significant when comparing the two groups. There were no serious drug-related adverse events.Conclusions/interpretation When included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes.Trial registration ClinicalTrials.gov NCT03590626 FUNDING: The current study was supported by an investigator-initiated study grant from Medanta-The Medicity's departmental research fund and a grant from the Endocrine and Diabetes Foundation (EDF), India. Graphical abstract.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reported liver fat reductions with GLP-1 mono-agonists and the GIP/GLP-1 dual agonist, tirzepatide, were lower than those observed with retatrutide, ranging from 32% after 24 weeks with dulaglutide and 47% after 52 weeks with tirzepatide, to approximately 50% after 72 weeks treatment with semaglutide8,18,19.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [18]
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Lavine, J. E. (2011) · JAMA · doi:10.1001/jama.2011.520 · Cited by 1,101
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c
Ferré, P., & Foufelle, F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01275.x · Cited by 704
A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver
Yamashita, H., Takenoshita, M., Sakurai, M., Bruick, R. K., Henzel, W. J., Shillinglaw, W., Arnot, D., & Uyeda, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161284298 · Cited by 682 · cited 1×
“element-binding protein (CREBP) and sterol-regulatory element-binding protein 1c (SREBP-1c) transcription factors, which are in turn stimulated by hyperglycaemia and hyperinsulinaemia, respectively [39, 40].”
BackgroundKuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · cited 3×
“0% [27]; had type 2 diabetes treated with metformin and/or dipeptidyl peptidase 4 (DPP-4) inhibitors and/or sulfonylurea and/or insulin, for whom treatment with dulaglutide was indicated due to poor diabetes control (HbA1c >53 mmol/mol [>7.”
BackgroundMethodResultSelf-citation4. Lifestyle Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s004 · Cited by 563
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550
Loomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J., Kono, Y., Bhatt, A., et al. (2015) · Hepatology · doi:10.1002/hep.27647 · Cited by 344
Mattar, S. G., Velcu, L. M., Rabinovitz, M., Demetris, A. J., Krasinskas, A. M., Barinas-Mitchell, E., Eid, G. M., Ramanathan, R., Taylor, D. S., & Schauer, P. R. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000179652.07502.3f · Cited by 341
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Cui, J., Philo, L., Nguyen, P., Hofflich, H., Hernandez, C., Bettencourt, R., Richards, L., Salotti, J., Bhatt, A., Hooker, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.021 · Cited by 326
Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome
Lee, J. S., Kim, S. H., Jun, D. W., Han, J. H., Jang, E. C., Park, J. Y., Son, B. K., Kim, S. H., Jo, Y. J., Park, Y. S., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1869 · Cited by 318
Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer In a Large U.S. Cohort
Patel, A. V., Rodriguez, C., Bernstein, L., Chao, A., Thun, M. J., & Calle, E. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0583 · Cited by 286
Trevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277
Wong, V. W.-S., Wong, G. L.-H., Yeung, D. K.-W., Abrigo, J. M., Kong, A. P.-S., Chan, R. S.-M., Chim, A. M.-L., Shen, J., Ho, C.-S., Woo, J., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.1 · Cited by 275
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272
Petit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
Mells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202
Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma
Hori, M., Takahashi, M., Hiraoka, N., Yamaji, T., Mutoh, M., Ishigamori, R., Furuta, K., Okusaka, T., Shimada, K., Kosuge, T., et al. (2014) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2014.5 · Cited by 160
Wu, W.-C., & Wang, C.-Y. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-77 · Cited by 158
Lee, J., Hong, S.-W., Chae, S. W., Kim, D. H., Choi, J. H., Bae, J. C., Park, S. E., Rhee, E.-J., Park, C.-Y., Oh, K.-W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031394 · Cited by 157
Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
Moreira, G., Azevedo, F., Ribeiro, L., Santos, A., Guadagnini, D., Gama, P., Liberti, E., Saad, M., & Carvalho, C. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.009 · Cited by 156
GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
He, Q., Sha, S., Sun, L., Zhang, J., & Dong, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.086 · Cited by 150
Johnson, J. A., Lee, A., Vinson, D., & Seale, J. P. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01898.x · Cited by 146 · cited 1×
“Alcohol assessment was documented using the AUDIT questionnaire [28].”
MethodSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133 · cited 2×
“However, two smaller studies did not show any benefit of liraglutide on liver fat [15, 16].”
BackgroundPatel, N. S., Peterson, M. R., Brenner, D. A., Heba, E., Sirlin, C., & Loomba, R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12237 · Cited by 127
Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
Zhou, J. Y., Poudel, A., Welchko, R., Mekala, N., Chandramani-Shivalingappa, P., Rosca, M. G., & Li, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172594 · Cited by 67
Zhu, W., Feng, P.-P., He, K., Li, S.-W., & Gong, J.-P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.134 · Cited by 55
Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis
Reeder, S. B. (2013) · Hepatology · doi:10.1002/hep.26543 · Cited by 50
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Fala, L. (2015) · PubMed Central · Cited by 28
Kawaguchi, T., Itou, M., Taniguchi, E., & Sata, M. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1826 · Cited by 24
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pieters-van den Bos, I. C., Vendrik, K. E. W., Hoekstra, T., Bruno, M. J., Diamant, M., van Raalte, D. H., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0836 · Cited by 23 · cited 2×
“One study did not find any reduction of pancreatic fat content (PFC) after 12 weeks of liraglutide therapy [26].”
Background
Cited by
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“…fat reductions with GLP-1 mono-agonists and the GIP/GLP-1 dual agonist, tirzepatide, were lower than those observed with retatrutide, ranging from 32% after 24 weeks with dulaglutide and 47% after 52 weeks with tirzepatide, to approximately 50% after 72 weeks treatment with semaglutide 8,18,19 .”
BackgroundAdvancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
“This is the largest and most updated assessment to date on the efficacy of GLP-1 RAs to specifically treat NAFLD or NASH that has also included the most recently published RCTs using two long-acting GLP-1 RAs, such as dulaglutide and semaglutide [33,34].”
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Metadata
- Authors
- Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., & Mithal, A.
- Affiliations
- Medanta The Medicity (IN)
- Corresponding author
- Kuchay, Mohammad S.
- ORCID
- Venue
- Diabetologia
- Published
- 2020-08-31
- Volume
- 63
- Issue
- 11
- Pages
- 2434-2445
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W3082461370
- Cited by
- 249
- References
- 41
- Citations by year
- 2026: 42 · 2025: 48 · 2024: 43 · 2023: 44 · 2022: 33 · 2021: 34 · 2020: 4
- FWCI
- 20.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- AstraZeneca
- Sanofi
- National Science Council
- Novo Nordisk
- Wockhardt
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, type 2 diabetes, non-alcoholic fatty liver disease, liver fat, GLP-1 receptor agonists, proton density fat fraction, pancreatic fat content, liver stiffness, gamma-glutamyl transferase, liver enzymes, adjunctive therapy, liver fibrosis
- MeSH terms
- Liraglutide, Alanine Transaminase, Aspartate Aminotransferases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Liver, Liver Function Tests, Recombinant Fusion Proteins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.